Mercury Laboratories Limited share price
BSE: MERCURYLAB
Key numbers
- Market cap
- ₹ 100.0 Cr
- Current price
- ₹ 833.00
- 52-week high / low
- ₹ 943 / 621
- Stock P/E
- 24.0
- Book value
- ₹ 483.9
- Dividend yield
- 0.42%
- ROCE
- 10.9%
- ROE
- 8.7%
- Debt to equity
- 0.15
- Sales growth (3 yrs)
- 0.3%
- Profit growth (3 yrs)
- -4.7%
- 1-year return
- -1.0%
About Mercury Laboratories Limited
Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides antihypertensive, galactagogue, PCOS and uterine disorders, haemostat, digestive enzyme, utertonic, anti-fungal, constipation, vitamin K1, Nutritional Vitamin D, nausea vomiting in Pregnancy, nutrional supplement for gynec, pediatric, surgeon, and physician applications. The company export its products comprising anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cough and cold, miscellaneous, and…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 18 | 19 | 18 | 20 | 16 |
| Operating profit | 2 | 2 | 3 | 2 | 1 |
| Net profit | 1 | 2 | 1 | 1 | 0 |
| EPS (₹) | 8.06 | 13.69 | 8.31 | 10.21 | 2.48 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.